This Penny Stock Is Insanely Undervalued – Sundial Growers (SNDL) Stock analysis

Let me know down below which penny stock is your favourite at the moment 👇🏾

Do you suggest me to hold on ZOM or sell some of it to buy SNDL?
( i love ZOM ).

Honestly debating between investing in it or not. I’m waiting for it to drop.

yeah they are doing a reverse split…its going to be hard

Made some quick cash with sndl. But deffo too risky to hold it 😂

Bitcoin is the future of crypto and the questions traders ask themselves now is if this is right time to invest? before jumping into conclusion i think you should take a look at things first. for the past few days the price of BTC has been fluctuating which means the market is currently unstable and you cant tell if it is going bearish or bullish. while others still continue to trade without the fear of making lose, others are being patient. it all depends on the pattern with which you trade and also the source of your signals. i would say trading has been going smoothly for me after accumulating over 8.5 BTC in just two weeks, with the trading strategy given to me by Tony Max. His methods are top notch and profitable and he can be contacted easily on Telegram ( @ Tony_signal22)  whatsapp :::::: +17149425639cheers.

Bought two calls on sndl. One at $1 for the 29th and one at .50 cents for 4/16. Just one contract each because I don’t have much capital. Ive been able to 3.5x my $600 original investments.
You should look into the psychedelic sector!! Mmedf and mycof are two I’m invested in

Why should we buy this stock

lets get monitized famm🔥🔥🔥🔥

Deffo still got room to run💥

I would rather buy CHUC 🚀🚀🚀

250 shares and holding 👌🏾

👉🏻👉🏻 ATNF (180 Life Sciences) Under the radar gem is an
understatement. Potentially 50X-100X current stock price or more.
Co-Founded by Prof. Raphael Mechoulam "THE GODFATHER Of Cannabis
Research" Best known for discovering the Endocannabinoid system and
isolating the two primary compounds, CBD and THC. ATNF has a Tiny 2.3
million share float and multi $10’s of BILLION and possible $100 Billion
dollar pipeline on the number #1 cause of all autoimmune diseases in
the world (Inflammation) and Chronic Pain Therapies with the absolute
Best Minds in the world. Dream Team Management created drugs and
companies that sold for many Billions. This could easily run 50 times
the current stock price. They are fully funded with grants also and cash
on hand. Risk/reward is amazing here. Market cap is tiny around $50
million. Patent portfolio alone is worth 8X the current stock price.

👉🏻Synthetic CBD Analogs (SCAs) for Pain and Inflammation•Safe &
non-psychoactive•Formulated to offer improved oral bioavailability (>
three-fold)•Rigorously tested in clinical trials for inflammatory pain
(efficacy and dosing)•Granted market approval by FDA, EMA and others•A
real alternative to unregulated consumption of medical cannabis or OTC
CBD (no clinical evidence, not FDA approved, unreliable composition,
unpredictable dosing and safety)

👉🏻Need: 125 Million Americans have chronic inflammatory conditions, 61
million have more then one. Over 400 Million worldwide suffer from
persistent pain, often associated with inflammatory diseases. 180 Life
sciences is focused on providing effective therapies.

Developing three families of novel drugs addressing significnt market
opportunities in inflammation, fibrosis and pain:
👉🏻👉🏻Anti-TNF for inflammation driven Fibrosis
👉🏻👉🏻Synthetic CBD analogs (SCAs) for inflammation and Pain
(Synthetic CBD analogs are man-made derivatives of cannabidiol
(CBD).These compounds have anti-inflammatory, analgesic and anxiolytic
properties, making it a potential treatment for arthritic conditions.
This program is led by Professor Raphael Mechoulam who discovered
tetrahydrocannabinol and cannabinol, the main compounds in cannabis, and
led pioneering research into the endocannabinoid system)
👉🏻👉🏻a7nAChR nicotinic agonist for inflammation

Numerous near-term inflection points for anti-TNF programs:
👉🏻First Clinical program fully enrolled in phase 2b/3 trial
👉🏻Two additional clinical programs projected to start 2H 2021
👉🏻First two anti-TNF clinical trials funded by UK grants and modest
180LS
investment
👉🏻Very efficient cash flow model

👉🏻👉🏻Strong IP portfolio with a long lifespan, providing coverage up
to 2039

👉🏻Prof Raphael Mechoulam CO-Founder, 180 LS•Godfather of cannabinoid
chemistry.Labeled as "THE GOD FATHER" of cannabis research, having
worked on the chemistry, pharmacology and clinical effects of natural
products, including cannabis for over 50 years. He isolated numerous
cannabinoids, including
the active constituent of cannabis, delta9-THC, and elucidated its
structure and CBD. This also paved the way to his discovery of 2AG and
anandamide, both endogenous cannabinoids in late 1990s. He has published
over 400 papers in esteemed scientific journals and be awarded several
notable prizes including the Israeli Prize in Exact Sciences in 2000,
NIDA discovery award in 2011, 2012 Rothschild Prize in Chemical Sciences
and Physical Sciences, and Lifetime achievement award at CannaMed in
2016. Currently his work focuses on generating novel cannabinoids and
anandamide-like compounds which are being developed as drugs.

https://www.cannabisfn.com/who-is-raphael-mechoulam-why-is-he-known-as-the-godfather-of-cannabis/

https://www.cannabis-conversation.com/blogs/episode80

https://www.forbes.com/sites/javierhasse/2020/07/12/dr-mechoulam/?sh=55138c7f6a45

https://merryjane.com/news/godfather-of-cannabis-isolated-a-new-weed-compound-that-has-profound-medical-value

180 Life Sciences is led by Dr. James Woody:
👉🏻Dr. James N. Woody CEO•Discovered Remicade at Centocor•Founded
Avidiaand Proteolix, which were sold to Amgen•GP of LatterellVenture
Partners•25+ years of pharmaceutical research and management
experience•General Manager of Roche Biosciences (Former Syntex)
Chief Executive Officer Jim Woody has more than 25 years of
pharmaceutical research and management expertise
He currently serves as Chairman of Oncomed Pharmaceuticals, where he was
previously a founder and CEO; he is also a General Partner at Latterell
Venture Partners, a venture capital group focusing on early-stage
healthcare companies
He has served in a variety of health and management roles including as
President of Roche Bioscience, and CSO and Senior Vice President of
R&D for Centocor.
At Centocor, Jim was part of the team that discovered Remicade, ($5.03
Billion in sales in 2019)used to treat arthritis and which is now one of
the best-selling drugs in the world.
He served as Commanding Officer and Director at the US Naval Medical
Research and Development Command in Bethesda, Maryland
In this role he was responsible for the surveillance, detection and
therapy for all biologic warfare agents and infectious diseases in the
First Gulf War; he was awarded the US Navy Legion of Merit for his
service
He holds an MD from Loma Linda University, and trained in pediatric
immunology at Duke University and Boston Children’s Hospital (Harvard)
He further holds a PhD in Immunology from the University of London, and
has co-authored more than 140 publications

👉🏻Prof Sir Marc Feldmann Co-Chairman•Pioneer of anti-TNF therapy,
world’s biggest drug class ($40 billion) Anti-TNF discovery eventually
led to Centocor’sacquisition by J&J for $4.9 Billion •7
International awards for Biomedical Innovation, including Crafoordand
Lasker Awards
Co-Chairman Professor Sir Marc Feldmann, AC FAA FRS FRCP Fmedsci is a
pre-eminent immunologist, and an Emeritus professor at the University of
Oxford.
At the Kennedy in Insitute in London in the 1980's, he identified TNF as
a target in the treatment of arthritis. With his research partner, Prof
Sir Ravinder Maini they led clinical trails of monocional antiTNF
antibody in treatment resistant rheumatoid arthritis, which Centercor
had generated and now called Infliximab, which J&J now sells as
Remicade.
Remicade was the main driver of the $4.9 Billion acquisition of Centocor
by Johnson and Johnson . Since its approval of Remicade has sold over
$50 Billion worldwide, and remains J&J's biggest selling drug.
Feldmann and Maini are credited for the generation of anti-TNFs as the
worlds biggest drug class since 2013, with global sales of $36 to $40
Billion in recent years. This major impact on medical therapy led to his
receiving a knighthood and also the Australian equivalent, Companion of
the order of Australia.
Sir Marc Feldmann is a fellow of the Royal Society, Australian Academy
of sciences and a Foreign Member of the National Academy of Sciences,
USA

👉🏻Prof Lawrence Steinman Co-Chairman•Discovered role of integrins, led
to Natalizumab, highly effective treatment for MS and IBD•Tysabri sold
to Royalty Pharam in 2017 for $3.25 Billion Member of National Academy
of Sciences, 4 International awards for Biomedical Innovation including
Charcot Prize; founder of Centocor
Prof Lawrence Steinman is currently is the George A. Zimmermann Endowed
Chair in Neurology department at Stanford University.
Professor Steinman has overseen success in the pharmaceuticals industry;
he was on the board of Centocor, sold to Johnson and Johnson for $4.9
Billion and was founder of Neurocrine Biosciences(NASDAQ:NBIX) which
went public in 1997

👉🏻Dr Jonathan Rothbard Chief Scientific Officer•Stanford University,
broad experience in small molecule development•Founder of 5 biotech
companies; Amylin sold to AstraZeneca and Bristol Myer Squibb for $5.4
Billion in 2012
Chief Scientific Officer Dr Jonathan Rothbard works in the
neurology department at Stanford University
Dr. Rothbard headed the mocecular Immunology Labortory at the Imperial
Cancer Research Fund in London in 1990, where he first worked with
Professor Sir Marc Feldmann
Dr Rothbard has been involved at the high level with start-up
pharmaceuticals discovery; in 1987 he founded Amylin in San Diego and
has also founded start-ups CellGate and Immulogic
Amylin was sold in 2012 to Brstol-Myers Squibb for $5.4 billion

👉🏻Prof Jagdeep Nanchahal Chairman of Clinical Advisory
Board•Surgeon-scientist, Leading 2b/3 trial funded by WellcomeTrust and
UKDept. of health•Fellow of the Royal College of Surgeons; discovered
new treatments for fibrosis.
Professor Nanchahal is a surgeon at the University of Oxford, focused on
defining the molecular mechanisms of common diseases such as fibrosis
He has pioneered the treatment of fibrosis of the hand(Dupuytren's
disease).